Search Results - "CHIAPPORI, Alberto A"

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial by Creelan, Benjamin C., Wang, Chao, Teer, Jamie K., Toloza, Eric M., Yao, Jiqiang, Kim, Sungjune, Landin, Ana M., Mullinax, John E., Saller, James J., Saltos, Andreas N., Noyes, David R., Montoya, Leighann B., Curry, Wesley, Pilon-Thomas, Shari A., Chiappori, Alberto A., Tanvetyanon, Tawee, Kaye, Frederic J., Thompson, Zachary J., Yoder, Sean J., Fang, Bin, Koomen, John M., Sarnaik, Amod A., Chen, Dung-Tsa, Conejo-Garcia, Jose R., Haura, Eric B., Antonia, Scott J.

“…Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small…”
Get full text

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK -rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study by Gadgeel, Shirish M, MD, Gandhi, Leena, MD, Riely, Gregory J, MD, Chiappori, Alberto A, MD, West, Howard L, MD, Azada, Michele C, MPH, Morcos, Peter N, PharmD, Lee, Ruey-Min, MD, Garcia, Linta, PharmD, Yu, Li, PhD, Boisserie, Frederic, MSc, Di Laurenzio, Laura, PhD, Golding, Sophie, MSc, Sato, Jotaro, MS, Yokoyama, Shumpei, MS, Tanaka, Tomohiro, MS, Ou, Sai-Hong Ignatius, Dr

“…Summary Background Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8–11 months while on…”
Get full text

Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer by Chen, Dung-Tsa, Chan, Wenyaw, Thompson, Zachary J, Thapa, Ram, Beg, Amer A, Saltos, Andreas N, Chiappori, Alberto A, Gray, Jhanelle E, Haura, Eric B, Rose, Trevor A, Creelan, Ben

“…Rationale Recent studies have discovered several unique tumor response subgroups outside of response classification by Response Evaluation Criteria for Solid…”
Get full text

Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients by Schabath, Matthew B, Nguyen, Anthony, Wilson, Patrick, Sommerer, Katelyn R, Thompson, Zachary J, Chiappori, Alberto A

“…Highlights • From 1986 to 2008, small cell lung cancer patient survival significantly improved. • Median survival time and 1-, 2.5- and 5-year survival rates…”
Get full text

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors by Hamid, Omid, Chiappori, Alberto A, Thompson, John A, Doi, Toshihiko, Hu-Lieskovan, Siwen, Eskens, Ferry A L M, Ros, Willeke, Diab, Adi, Spano, Jean-Philippe, Rizvi, Naiyer A, Wasser, Jeffrey S, Angevin, Eric, Ott, Patrick A, Forgie, Alison, Yang, Wenjing, Guo, Cen, Chou, Jeffrey, El-Khoueiry, Anthony B

“…BackgroundIvuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This…”
Get full text

Variance of SUVs for FDG-PET/CT is Greater in Clinical Practice Than Under Ideal Study Settings by Kumar, Virendra, Nath, Kavindra, Berman, Claudia G, Kim, Jongphil, Tanvetyanon, Tawee, Chiappori, Alberto A, Gatenby, Robert A, Gillies, Robert J, Eikman, Edward A

“…PURPOSEMeasurement variance affects the clinical effectiveness of PET-based measurement as a semiquantitative imaging biomarker for cancer response in…”
Get full text

Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel by Ozakinci, Hilal, Alontaga, Aileen Y., Cano, Pedro, Koomen, John M., Perez, Bradford A., Beg, Amer A., Chiappori, Alberto A., Haura, Eric B., Boyle, Theresa A.

“…The translation of gene expression profiles of SCLC to clinical testing remains relatively unexplored. In this study, gene expression variations in SCLC were…”
Get full text

Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis by Hembree, Timothy N, Teer, Jamie K, Hakam, Ardeshir, Chiappori, Alberto A

“…Uterine carcinosarcoma, a rare gynecological malignancy, often presents at the advanced stage with a poor prognosis because current therapies have not improved…”
Get more information

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies by HOMSI, Jade, SIMON, George R, ANGIULI, Patrizia, EISENFELD, Amy, SULLIVAN, Daniel M, DAUD, Adil I, GARRETT, Chris R, SPRINGETT, Gregory, DE CONTI, Ronald, CHIAPPORI, Alberto A, MUNSTER, Pamela N, BURTON, Michelle K, STROMATT, Scott, ALLIEVI, Claudia

“…Purpose: CT-2106 is a 20( S )-camptothecin poly- l -glutamate conjugate. This linkage stabilizes the active lactone form of camptothecin and enhances aqueous…”
Get full text

Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer by JÄNNE, Pasi A, VON PAWEL, Joachim, DASSE, Kathy, SHEERAN, Meredith, BONOMI, Philip D, COHEN, Roger B, CRINO, Lucio, BUTTS, Charles A, OLSON, Steven S, EISEMAN, Irene A, CHIAPPORI, Alberto A, YEAP, Beow Y, LENEHAN, Peter F

“…To evaluate the efficacy of the pan-ERBB inhibitor, CI-1033, in platinum-refractory or recurrent advanced-stage non-small-cell lung cancer (NSCLC). This…”
Get full text

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model by Sarcar, Bhaswati, Gimbrone, Nicholas T., Wright, Gabriela, Remsing Rix, Lily L., Gordian, Edna R., Rix, Uwe, Chiappori, Alberto A., Reuther, Gary W., Santiago‐Cardona, Pedro G., Muñoz‐Antonia, Teresita, Cress, William Douglas

“…Lung cancer patients with mutations in epidermal growth factor receptor (EGFR) benefit from treatments targeting tyrosine kinase inhibitors (TKIs). However,…”
Get full text

A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses by Boyle, Theresa A., Quinn, Gwendolyn P., Schabath, Matthew B., Muñoz‐Antonia, Teresita, Saller, James J., Duarte, Luisa F., Hair, Laura S., Teer, Jamie K., Chiang, Derek Y., Leary, Rebecca, Wong, Connie C., Savchenko, Alexander, Singh, Angad P., Charette, LaSalette, Mendell, Kate, Gorgun, Gullu, Antonia, Scott J., Chiappori, Alberto A., Creelan, Benjamin C., Gray, Jhanelle E., Haura, Eric B.

“…Background For the advancement of cancer research, the collection of tissue specimens from drug‐resistant tumors after targeted therapy is crucial. Although…”
Get full text

Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma by Raj, Shailaja, Bui, Marilyn M., Springett, Gregory, Conley, Anthony, Lavilla-Alonso, Sergio, Zhao, Xiuhua, Chen, Dungsa, Haysek, Randy, Gonzalez, Ricardo, Letson, G. Douglas, Finkelstein, Steven Eric, Chiappori, Alberto A., Gabrilovitch, Dmitry I., Antonia, Scott J.

“…Purpose. Patients with large >5 cm, high-grade resectable soft tissue sarcomas (STS) have the highest risk of distant metastases. Previously we have shown that…”
Get full text

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer by CHIAPPORI, Alberto A, HAURA, Eric, SIMON, George, ANTONIA, Scott, SULLIVAN, Daniel M, BEPLER, Gerold, RODRIGUEZ, Francisco A, BOULWARE, David, KAPOOR, Rachna, NEUGER, Anthony M, LUSH, Richard, PADILLA, Barbara, BURTON, Michelle, WILLIAMS, Charles

“…Purpose: Endothelins and their cell membrane receptors (ET A R and ET B R) are implicated in neoplastic pathogenesis. Atrasentan, a potent, selective ET A R…”
Get full text

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial by Horn, Leora, Wang, Ziping, Wu, Gang, Poddubskaya, Elena, Mok, Tony, Reck, Martin, Wakelee, Heather, Chiappori, Alberto A, Lee, Dae Ho, Breder, Valeriy, Orlov, Sergey, Cicin, Irfan, Cheng, Ying, Liu, Yunpeng, Fan, Yun, Whisenant, Jennifer G, Zhou, Yi, Oertel, Vance, Harrow, Kim, Liang, Chris, Mao, Li, Selvaggi, Giovanni, Wu, Yi-Long

“…Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system efficacy for patients with…”
Get more information

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors by CHIAPPORI, Alberto A, ECKHARDT, S. Gail, MEKHAIL, Tarek, O'BRYANT, Cindy L, CREAVEN, Patrick J, BUKOWSKI, Ronald, SULLIVAN, Daniel M, IKEDA, Minoru, YANO, Yoshitaka, YAMADA-SAWADA, Takuko, KAMBAYASHI, Yoshikaze, TANAKA, Kazushige, JAVLE, Milind M

“…Purpose: Matrix metalloproteinases (MMP) play a fundamental role in cancer development and progression. S-3304 is a potent, orally active, noncytotoxic…”
Get full text

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer by Chiappori, Alberto A, Creelan, Ben, Tanvetyanon, Tawee, Gray, Jhanelle E, Haura, Eric B, Thapa, Ram, Barlow, Margaret L, Chen, Zhihua, Chen, Dung Tsa, Beg, Amer A, Boyle, Theresa A, Castro, Julio, Morgan, Liza, Morris, Erick, Aregay, Mehreteab, Hurtado, Felipe K, Manenti, Luigi, Antonia, Scott

“…The adenosine 2A receptor (A2AR) mediates the immunosuppressive effects of adenosine in the tumor microenvironment and is highly expressed in non-small cell…”
Get full text

Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer by Chiappori, Alberto A, Zheng, Zhong, Chen, Tingan, Rawal, Bhupendra, Schell, Michael J, Mullaney, Brian P, Bepler, Gerold

“…One-size-fits-all chemotherapy does not improve survival in patients with small cell lung cancer (SCLC). Excision repair cross-complementing group 1 (ERCC1),…”
Get more information

A phase I study of indoximod in patients with advanced malignancies by Soliman, Hatem H, Minton, Susan E, Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A, Roberts, John D, Link, Charles, Vahanian, Nicholas N, Mautino, Mario, Streicher, Howard, Sullivan, Daniel M, Antonia, Scott J

“…Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum…”
Get full text

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer by Chiappori, Alberto A., Williams, Charles C., Gray, Jhanelle E., Tanvetyanon, Tawee, Haura, Eric B., Creelan, Ben C., Thapa, Ram, Chen, Dung-Tsa, Simon, George R., Bepler, Gerold, Gabrilovich, Dmitry I., Antonia, Scott J.

“…Small cell lung cancer TP53 mutations lead to expression of tumor antigens that elicits specific cytotoxic T-cell immune responses. In this phase II study,…”
Get full text